Pharmacyclics expects employees to sell shares during next open trading Pharmacyclics said in its earnings release this morning that during the next open trading window which commences on November 7, it expects certain employees may exercise options they hold, and sell the shares immediately following the exercise. The company added that it’s CEO and Chairman, Robert Duggan, does not anticipate selling any of his shares at the present time.
FDA expands use of Imbruvica to rare form of cancer The FDA expanded the approved use of Imbruvica for previously treated patients with Waldenström’s macroglobulinemia, a rare form of cancer that begins in the body’s immune system. The drug received a breakthrough therapy designation for this use. The product's new use is being approved more than two months ahead of its prescription drug user fee goal date of April 17, the date the FDA was scheduled to complete review of the drug application. Imbruvica is co-marketed by Pharmacyclics (PCYC) and Johnson & Johnson's (JNJ) Janssen Biotech unit.